Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Orlando Immunology Center
ClinicalTrials.gov Identifier:
NCT00312169
First received: April 5, 2006
Last updated: May 20, 2008
Last verified: May 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2008
  Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)